Latest news
Loading news…
Sevion Therapeutics
ClosedOperating status — whether the company still runs independently. “Closed” usually means it was acquired, merged, or shut down.🔥 LowHeat score — how much recent activity & attention the company has (web traffic, news, hiring). San Diego, California, United States Founded 1964 11-50 employees For Profit
Sevion Therapeutics is a biopharmaceutical company that discovers and develops entirely new therapeutic classes for the treatment of cancer.
Sevion Therapeutics was acquired by Eloxx in 2017.
Total Funding
Available in Pro Last Funding
Available in Pro Acquisitions
0
Monthly Visits
Available in Pro Contacts
0
Patents
3
Company Details
Funding & Financials
Pro- Total funding
- Funding rounds
- Last funding
- Last funding type
- Last funding date
- Funding status
- Total equity funding
- Revenue range
IPO & Stock
- IPO status
- Delisted
- Ticker
- SVON
- Exchange
- OTCQB
- IPO date
- Oct 3, 2014
- Delisted
- Dec 19, 2017
Web Traffic
Pro- Monthly visits
- Global traffic rank
- 6-mo avg visits
- Visit duration (s)
- Pages / visit
- Bounce rate
- Rank change (mo)
Technology & IP
- Active technologies
- 5
- Active products
- 16
- Patents granted
- 3
- Trademarks
- 0
- Top patent class
- c07
- IT spend
- $101K
Company Info
- Founded
- 1964
- Employees
- 11-50
- Operating status
- Closed
- Company type
- For Profit
- Org types
- company
- Founders
- 2
- News articles
- 1
- HQ
- San Diego, California, United States
- Region
- Greater San Diego Area, West Coast, Western US
- Exit date
- Oct 3, 2014
- Closed
- Dec 19, 2017
Signals & Scores
- Heat score
- Low
- Trend (7d)
- -0.2
- Trend (30d)
- 1.9
- Trend (90d)
- 1.7
Key People at Sevion Therapeutics
President & CEO & Director
CEO
Explore 200,000+ acquisitions — free
Filter the full database across sectors, companies, dates, and deal sizes. No signup, no paywall.
Recent News related to Sevion Therapeutics
Loading news…
FAQs about Sevion Therapeutics
People who checked this page also checked these
Browse the full Acquirezy directory.